English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62476
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorGarcía-Alfonso, Pilar-
dc.contributor.authorGarcía-Carbonero, Rocío-
dc.contributor.authorNavarro, Samuel-
dc.date.accessioned2012-12-11T16:09:33Z-
dc.date.available2012-12-11T16:09:33Z-
dc.date.issued2012-
dc.identifierissn: 1699-8855-
dc.identifier.citationRevista Española de Patología 45(3): 130-144 (2012)-
dc.identifier.urihttp://hdl.handle.net/10261/62476-
dc.description.abstractThis consensus is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Based on scientific evidence of the use of biomarkers, it recommends diagnostic and treatment guidelines for the management of patients with hereditary, localised and advanced colorectal carcinoma (CRC). The aim of the consensus is to improve healthcare and the use of resources, which will result in increased patient benefit. Taking into consideration data currently available, the group of experts recommends testing for microsatellite instability in patients with localised CRC, as this is a strong predictive factor useful in deciding the choice of adjuvant treatment. However, although the ColoPrint ® and Oncotype Dx ® gene expression signatures have been shown to have prognostic value, no consensus yet exists as to their clinical use. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-epidermal growth factor receptor (EGFR) treatment, such as cetuximab or panitumumab. However, at present, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, is not indicated as a routine procedure as it does not influence choice of treatment. Other important issues addressed include organisational requirements, necessary quality controls for the correct testing of these biomarkers as well as the pertinent legal implications. © 2012 SEAP y SEC.-
dc.description.sponsorshipSEOM and SEAP acknowledge the financial support for this project of unrestricted grants from Amgen S.A.; Merck S.L.; Roche Farma of Spain and Sanofi.-
dc.language.isoeng-
dc.publisherSpringer-
dc.rightsclosedAccess-
dc.titleGuidelines for biomarker testing in advanced colorectal carcinoma. A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology-
dc.title.alternativeRecomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica-
dc.typeartículo-
dc.identifier.doi10.1016/j.patol.2012.05.001-
dc.relation.publisherversionhttp://doi.org/10.1016/j.patol.2012.05.001-
dc.date.updated2012-12-11T16:09:33Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.